InMed Pharmaceuticals (INM) Equity Average (2019 - 2026)

InMed Pharmaceuticals has reported Equity Average for 8 years, with the latest figure at $8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 24.81% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2026 stood at $8.2 million (up 24.81% YoY), and the FY2025 full-year result was $11.3 million, up 6.31% from the prior year.
• Equity Average for Q1 2026 stood at $8.2 million, down from $10.6 million in the prior quarter.
• The five-year high for Equity Average was $13.4 million in Q1 2023, with the low at $1.3 million in Q3 2023.
• Historically, Equity Average has averaged $9.4 million across 5 years, with a median of $10.2 million in 2024.
• Annual changes were most pronounced in 2023 — Equity Average tumbled 87.5% — and 2024, when it jumped 600.8%.
• InMed Pharmaceuticals' Equity Average stood at $12.7 million in 2022, then sank by 87.4% to $1.6 million in 2023, then soared by 356.39% to $7.3 million in 2024, then surged by 45.28% to $10.6 million in 2025, then declined by 22.19% to $8.2 million in 2026.
• The last three Equity Average figures came in at $8.2 million (Q1 2026), $10.6 million (Q4 2025), and $12.5 million (Q3 2025), per Business Quant data.